Evidence map›Paper›PMID 33571168›Full record

Trial reportJCI insight2021

Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.

Michele L Donato, Steven Park, Melissa Baker, Robert Korngold, Alison Morawski, Xue Geng, Ming Tan, Andrew Ip, Stuart Goldberg, Scott Rowley and 38 more

Open access · goldAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JCI insight, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 8 pooled it
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 8 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

48 authors at 3 institutions in 1 country.

Michele L DonatoJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Steven ParkHackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Melissa BakerJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Robert KorngoldHackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Alison MorawskiJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Xue GengDepartment of Biostatistics, Bioinformatics and Biomathematics, Georgetown University, Washington, DC, USA.
Ming TanDepartment of Biostatistics, Bioinformatics and Biomathematics, Georgetown University, Washington, DC, USA.
Andrew IpJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Stuart GoldbergJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Scott RowleyJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Kar ChowHackensack University Medical Center, Hackensack, New Jersey, USA.
Emily BrownJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Joshua ZenreichJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Phyllis McKiernanJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Kathryn ButtnerJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Anna UllrichJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Laura LongJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Rena FeinmanHackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Andrea RicourtJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Marlo KempJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Mariefel VendivilJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Hyung SuhJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Bindu BalaniHackensack University Medical Center, Hackensack, New Jersey, USA.
Cristina CicognaHackensack University Medical Center, Hackensack, New Jersey, USA.
Rani SebtiHackensack University Medical Center, Hackensack, New Jersey, USA.
Abdulla Al-KhanHackensack University Medical Center, Hackensack, New Jersey, USA.
Steven SperberHackensack University Medical Center, Hackensack, New Jersey, USA.
Samit DesaiHackensack University Medical Center, Hackensack, New Jersey, USA.
Stacey FanningHackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Danit AradHackensack University Medical Center, Hackensack, New Jersey, USA.
Ronaldo GoHackensack University Medical Center, Hackensack, New Jersey, USA.
Elizabeth TamHackensack University Medical Center, Hackensack, New Jersey, USA.
Keith RoseHackensack University Medical Center, Hackensack, New Jersey, USA.
Sean SadikotHackensack University Medical Center, Hackensack, New Jersey, USA.
David SiegelJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Martin GutierrezJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Tatyana FeldmanJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Andre GoyJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Andrew PecoraJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Noa BiranJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Lori LeslieJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Alfred GillioHackensack University Medical Center, Hackensack, New Jersey, USA.
Sarah TimmapuriHackensack University Medical Center, Hackensack, New Jersey, USA.
Michele BoonstraJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Sam SingerJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Sukhdeep KaurJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Ernest RichardsJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
David S PerlinHackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Hackensack University Medical Center · USHackensack Meridian Health · USGeorgetown University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we report on a phase IIa study to determine the intubation rate, survival, viral clearance, and development of endogenous Abs in patients with COVID-19 pneumonia treated with convalescent plasma (CCP) containing high levels of neutralizing anti-SARS-CoV-2 Abs. Radiographic and laboratory evaluation confirmed all 51 treated patients had COVID-19 pneumonia. Fresh or frozen CCP from donors with high titers of neutralizing Abs was administered. The nonmechanically ventilated patients (n = 36) had an intubation rate of 13.9% and a 30-day survival rate of 88.9%, and the overall survival rate for a comparative group based on network data was 72.5% (1625/2241). Patients had negative nasopharyngeal swab rates of 43.8% and 73.0% on days 10 and 30, respectively. Patients mechanically ventilated had a day-30 mortality rate of 46.7%; the mortality rate for a comparative group based on network data was 71.0% (369/520). All evaluable patients were found to have neutralizing Abs on day 3 (n = 47), and all but 1 patient had Abs on days 30 and 60. The only adverse event was a mild rash. In this study on patients with COVID-19 disease, we show therapeutic use of CCP was safe and conferred transfer of Abs, while preserving endogenous immune response.

Indexed as

PlasmaSeverity of Illness IndexAgedAntibodies, NeutralizingAntibodies, ViralConvalescenceCOVID-19COVID-19 SerotherapyFemaleHumansImmunization, PassiveImmunocompromised HostImmunoglobulin GMaleMiddle AgedPneumoniaAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GCOVID-19Immunotherapy

Identifiers

PMID33571168
PMCPMC8026191
OpenAlexW3126773711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.